In this Review article we summarize our current understanding about the biology of pathogenic KMT2A‐complex function in cancer, specifically leukemia, and give a systematic overview of lessons learned from recent clinical and preclinical studies using Menin inhibitors. This evidence concerns the gene KMT2A and leukemia.